TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35982223

Group type: EXPERIMENTAL
Intervention: anodal tDCS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: theta tACS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: theta-oscillatory tDCS (otDCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 40
Study: 32081221

Group type: EXPERIMENTAL
Intervention: Bladder catheterization (group A)
Number of subjects: 160

Group type: COMPARATOR
Intervention: As-needed catheterization (group B)
Number of subjects: 160
Study: 34617803

Group type: COMPARATOR
Intervention: SFFH from days 0 to 2 after fracture (Group B)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SFFH from days 3 to 9 (Group C)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SFFH from days 10 to 14 (Group D)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Group B + interleukin 1 receptor antagonist (IL-1Ra) (Group E)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Group B + doxycycline (Group F)
Number of subjects: 54
Study: 34107543

Group type: EXPERIMENTAL
Intervention: Health Information Exchange (HIE) with advice from specialists (n=518, 38% male, mean age 76±7 years)
Number of subjects: 1092

Group type: COMPARATOR
Intervention: No advice from specialists (Control group) (n=521, 39% male, mean age 75±7 years)
Number of subjects: 1092
Study: 33167911

Group type: EXPERIMENTAL
Intervention: Thiamine 200 mg every 12 hours for 7 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo every 12 hours for 7 days
Number of subjects: 50
Study: 35093666

Group type: EXPERIMENTAL
Intervention: Biofeedback training via a mobile insole system (Loadsol®)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional training using a bathroom scale
Number of subjects: 24
Study: 33251643

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 32368972

Group type: EXPERIMENTAL
Intervention: ABCB1 variants (rs1128503, rs2032582, rs1045642)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: VDR variants (rs11568820, rs1540339, rs1544410, rs2228570, rs3782905, rs7975232)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: TPMT variants (rs1142345, rs1800460)
Number of subjects: 131
Study: 34913089

Group type: EXPERIMENTAL
Intervention: Conservative fluid administration and active deresuscitation (removal of accumulated fluid using diuretics or ultrafiltration)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Conservative fluid administration and active deresuscitation
Number of subjects: 180
Study: 32809843

Group type: EXPERIMENTAL
Intervention: Inhaled AZD1419 (1, 4, or 8 mg; n=40)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 81
Study: 34171086

Group type: EXPERIMENTAL
Intervention: WOOP intervention (spousal care partners received WOOP training immediately after baseline)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (spousal care partners received WOOP training after a 3-month follow-up interview)
Number of subjects: 90
Study: 34462184

Group type: EXPERIMENTAL
Intervention: Self-directed rehabilitation (SDR) program using a smartwatch and mobile application
Number of subjects: 337

Group type: COMPARATOR
Intervention: Formal physical therapy (PT)
Number of subjects: 337
Study: 35080681

Group type: EXPERIMENTAL
Intervention: Sodium citrate (Utix sachets) administered three times per day until stent removal
Number of subjects: 115

Group type: COMPARATOR
Intervention: No administration of Utix sachets (control group)
Number of subjects: 115
Study: 36170002

Group type: EXPERIMENTAL
Intervention: InterWalk app-based interval walking training (IWT)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Standard care + InterWalk app-based interval walking training (IWT)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Standard care (StC)
Number of subjects: 214
Study: 32056267

Group type: EXPERIMENTAL
Intervention: Single water swallows in the supine position
Number of subjects: 438

Group type: COMPARATOR
Intervention: Single water swallows in the upright position
Number of subjects: 438

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Single water swallows in the supine position with solid test meal
Number of subjects: 438
Study: 34461742

Group type: EXPERIMENTAL
Intervention: 10 mg ITI-214
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 30 mg ITI-214
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 90 mg ITI-214
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 36281666

Group type: EXPERIMENTAL
Intervention: Low-dose pioglitazone
Number of subjects: 3494

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3494
Study: 34340527

Group type: EXPERIMENTAL
Intervention: THX‐110 (Δ9‐THC 10 mg daily and PEA 800 mg daily)
Number of subjects: 16
Study: 32701984

Group type: EXPERIMENTAL
Intervention: Verum acupuncture treatment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 70
Study: 36435544

Group type: EXPERIMENTAL
Intervention: Narrative Therapy (NT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Waitlist Control Group (WCG)
Number of subjects: 72
Study: 33675344

Group type: EXPERIMENTAL
Intervention: EPA and DHA (3.36 g)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 285
Study: 35638561

Group type: EXPERIMENTAL
Intervention: CJM112 300 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 35746869

Group type: EXPERIMENTAL
Intervention: D1/D5-R antagonist (SCH-23390 hydrochloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D2/D3-R antagonist (Eticlopride hydrochloride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 0
Study: 33028548

Group type: EXPERIMENTAL
Intervention: Bilateral interarcuair decompression
Number of subjects: 174

Group type: COMPARATOR
Intervention: Laminectomy
Number of subjects: 174
Study: 35191215

Group type: EXPERIMENTAL
Intervention: LEU-PRO
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: LEU-PRO+n-3
Number of subjects: 83

Group type: COMPARATOR
Intervention: CON
Number of subjects: 83
Study: 33058406

Group type: EXPERIMENTAL
Intervention: Body mass and BMI values from 2000 to 2006
Number of subjects: 2691

Group type: EXPERIMENTAL
Intervention: Body mass and BMI values from 2006 to 2018
Number of subjects: 2691

Group type: EXPERIMENTAL
Intervention: Motor tests results from 2000 to 2006
Number of subjects: 2691

Group type: EXPERIMENTAL
Intervention: Motor tests results from 2006 to 2018
Number of subjects: 2691

Group type: EXPERIMENTAL
Intervention: Body height changes from 2000 to 2018
Number of subjects: 2691

Group type: EXPERIMENTAL
Intervention: Correlation between body mass/BMI and motor tests
Number of subjects: 2691
Study: 32243432

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No-stress control condition
Number of subjects: 12
Study: 35636696

Group type: EXPERIMENTAL
Intervention: Osimertinib plus bevacizumab (80 mg daily + 15 mg/kg every 3 weeks)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Osimertinib monotherapy (80 mg daily)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Osimertinib plus bevacizumab
Number of subjects: 122

Group type: COMPARATOR
Intervention: Osimertinib monotherapy
Number of subjects: 122
Study: 33860476

Group type: EXPERIMENTAL
Intervention: nonivamide‐nicoboxil cream
Number of subjects: 13

Group type: COMPARATOR
Intervention: placebo cream
Number of subjects: 13
Study: 35787482

Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 124
Study: 34020669

Group type: EXPERIMENTAL
Intervention: Preconception care (PCC) services
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Optimizing psychological health
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Education status of mother
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Time spent to access nearby health facilities
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Availability of PCC unit
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Mother’s knowledge on PCC
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Being a model household
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Women’s autonomy in decision making
Number of subjects: 591
Study: 32270385

Group type: EXPERIMENTAL
Intervention: KONTAKT© social skills group training
Number of subjects: 17
Study: 36049698

Group type: EXPERIMENTAL
Intervention: Capsaicin cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hand cream (control group)
Number of subjects: 0
Study: 34225789

Group type: EXPERIMENTAL
Intervention: degarelix plus best supportive care
Number of subjects: 198

Group type: COMPARATOR
Intervention: placebo plus best supportive care
Number of subjects: 198
Study: 36065786

Group type: EXPERIMENTAL
Intervention: BI 695501 for 48 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Humira for 24 weeks followed by BI 695501 for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Humira
Number of subjects: 0
Study: 33888356

Group type: EXPERIMENTAL
Intervention: Intense neoadjuvant androgen deprivation therapy (ADT) followed by radical prostatectomy (RP)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Intense neoadjuvant ADT
Number of subjects: 201
Study: 32791015

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation for 83 days, average consumption 74% of the intervention period
Number of subjects: 7

Group type: COMPARATOR
Intervention: Historical controls (N = 22)
Number of subjects: 7
Study: 35649189

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 34726574

Group type: EXPERIMENTAL
Intervention: V114 administered concomitantly with QIV
Number of subjects: 1200

Group type: COMPARATOR
Intervention: QIV plus placebo (non-concomitant group)
Number of subjects: 1200
Study: 34384427

Group type: EXPERIMENTAL
Intervention: My Therapy (self-management program) in addition to usual care
Number of subjects: 2160

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2160

Group type: EXPERIMENTAL
Intervention: My Therapy (self-management program)
Number of subjects: 2160
Study: 35397432

Group type: EXPERIMENTAL
Intervention: Avelumab plus axitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study: 32120870

Group type: EXPERIMENTAL
Intervention: Generic health literacy measured with the 'Measurement of Health Literacy Among Adolescents-Questionnaire' (MOHLAA-Q)
Number of subjects: 6608

Group type: EXPERIMENTAL
Intervention: Health behavior, subjective health status, personal and social resources, socio-demographic and social factors, and health services use
Number of subjects: 6608

Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 6608
Study: 36115928

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy (RT) for well-differentiated liposarcoma (n = 208)
Number of subjects: 3911

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy (RT) for dedifferentiated liposarcoma (n = 290)
Number of subjects: 3911

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 3911
Study: 33232647

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-Negative Pressure Wound Therapy (Non-NPWT)
Number of subjects: 15
Study: 32951766

Group type: EXPERIMENTAL
Intervention: Manual cervical manipulation
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Instrument-assisted cervical manipulation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 59
Study: 36295786

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (25,000 IU weekly)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 90
Study: 33386530

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Chronic Pain (CBT‐CP) delivered either in person or by interactive voice response for 10 weeks
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Walking program as part of CBT‐CP
Number of subjects: 125
Study: 33939497

Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 955

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 955
Study: 32441709

Group type: EXPERIMENTAL
Intervention: Endoscopic partial middle‐turbinectomy in addition to endoscopic sinus surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery without middle turbinectomy
Number of subjects: 90
Study: 35139097

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 34369697

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Baliao points combined with oral mifepristone (2 tablets daily)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Oral mifepristone (2 tablets daily)
Number of subjects: 58
Study: 35302842

Group type: EXPERIMENTAL
Intervention: Case rate maps
Number of subjects: 0

Group type: COMPARATOR
Intervention: County-level COVID case counts maps
Number of subjects: 0
Study: 33208625

Group type: EXPERIMENTAL
Intervention: CHO PET quantitative features
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: SUV-based features
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: SUVmax and total lesion CHO uptake
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Five alternative features (2 shape features and 3 SUV-based features)
Number of subjects: 39
Study: 32957612

Group type: EXPERIMENTAL
Intervention: 336.4 mg of decaffeinated green tea catechins (GTC) after a single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 336.4 mg of decaffeinated green tea catechins (GTC) after 12 weeks of daily intake
Number of subjects: 0
Study: 36175971

Group type: EXPERIMENTAL
Intervention: RO-IMPT with 5 mm geometric uncertainties
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RO-IMPT with 3 mm geometric uncertainties
Number of subjects: 26

Group type: COMPARATOR
Intervention: RO-IMPT
Number of subjects: 26
Study: 33726718

Group type: EXPERIMENTAL
Intervention: ICG-hyaluronic acid mixture 0.1 mL (Test Group 1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ICG-hyaluronic acid mixture 0.2 mL (Test Group 2)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Activated charcoal (Control Group)
Number of subjects: 44
Study: 32757521

Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD
Number of subjects: 849

Group type: COMPARATOR
Intervention: Transvenous ICD
Number of subjects: 849
Study: 35276764

Group type: EXPERIMENTAL
Intervention: Aged black garlic (ABG) extract 250 mg (1.25 mg SAC)/tablet/day
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 32709590

Group type: EXPERIMENTAL
Intervention: McKenzie‐based self‐management exercise and education program
Number of subjects: 262

Group type: COMPARATOR
Intervention: Single advice session over the phone
Number of subjects: 262
Study: 35428594

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided manual lymphatic drainage (MLD)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Traditional manual lymphatic drainage (MLD)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo manual lymphatic drainage (MLD)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided MLD
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Traditional MLD
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo MLD
Number of subjects: 194
Study: 34908913

Group type: EXPERIMENTAL
Intervention: Artificial intelligence medical intervention
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 447
Study: 32291223

Group type: EXPERIMENTAL
Intervention: Mobilisation with movement (MWM) plus exercises and advice
Number of subjects: 67

Group type: COMPARATOR
Intervention: Exercises and advice
Number of subjects: 67
Study: 35303118

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam
Number of subjects: 0
Study: 35894292

Group type: EXPERIMENTAL
Intervention: Baby-Led Introduction to SolidS (BLISS)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (traditional spoon-feeding)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Breast milk consumption
Number of subjects: 101
Study: 34162365

Group type: EXPERIMENTAL
Intervention: Single injection of Crosslinked Hyaluronic Acid Platform Hyaluronan (CHAP-HA)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Three injections of linear hyaluronan (linear-HA)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: CHAP-HA
Number of subjects: 140

Group type: COMPARATOR
Intervention: linear-HA
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Both CHAP-HA and linear-HA
Number of subjects: 140
Study: 32432566

Group type: EXPERIMENTAL
Intervention: Stepwise selection algorithm for joint selection of fixed and random effects in mixed-effects models
Number of subjects: 0
Study: 34657640

Group type: EXPERIMENTAL
Intervention: L-arabinose (7.5 g) co-ingested with 50 g sucrose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (50 g sucrose without L-arabinose)
Number of subjects: 12
Study: 32331937

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU
Number of subjects: 44

Group type: COMPARATOR
Intervention: 1 ml sodium chloride 0.9 (placebo)
Number of subjects: 44
Study: 33908312

Group type: EXPERIMENTAL
Intervention: MR stimulation (0.4 mg fludrocortisone + placebo)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: NMDA-R stimulation (placebo + 250 mg D-cycloserine)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: MR + NMDA-R stimulation (fludrocortisone + DCS)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (no pharmacological stimulation)
Number of subjects: 116
Study: 32718702

Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) supplementation to the CPB circuit (40-ppm NO during CPB)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) supplementation to the CPB circuit
Number of subjects: 96
Study: 32150489

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus pemetrexed-platinum
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo plus pemetrexed-platinum
Number of subjects: 616
Study: 35421222

Group type: EXPERIMENTAL
Intervention: Sitting Together and Reaching To Play
Number of subjects: 150

Group type: COMPARATOR
Intervention: Movement, Orientation, Repetition, Exercise Physical Therapy
Number of subjects: 150
Study: 33593332

Group type: EXPERIMENTAL
Intervention: Counseling and nicotine replacement for 8 weeks, plus ongoing proactive outreach calls inviting reengagement in treatment.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Brief education and referral to the state quit line.
Number of subjects: 38
Study: 33040018

Group type: EXPERIMENTAL
Intervention: Pregnant women with live born singletons
Number of subjects: 381
Study: 32521007

Group type: EXPERIMENTAL
Intervention: Household approach (decolonization performed by all household members)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Personalized approach (decolonization performed only by household members who experienced SSTI)
Number of subjects: 102
Study: 34915839

Group type: EXPERIMENTAL
Intervention: Hospital-based secondary preventive care with consultations at 2 weeks, 3 months, 6 months, and 1 year after the index event and annually for up to 5 years.
Number of subjects: 1540

Group type: EXPERIMENTAL
Intervention: Hospital-based secondary preventive care
Number of subjects: 1540

Group type: COMPARATOR
Intervention: Primary health care follow-up
Number of subjects: 1540
Study: 35731756

Group type: EXPERIMENTAL
Intervention: BCI-robotic therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Robotic therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 30
Study: 33243567

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 79
Study: 33921227

Group type: EXPERIMENTAL
Intervention: HHCR (Hederacoside C from ivy leaf dry extracts and berberine from Coptidis rhizome dry extracts)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: HHCR
Number of subjects: 304
Study: 33051032

Group type: EXPERIMENTAL
Intervention: Habit reversal training (HRT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 40
Study: 35170228

Group type: EXPERIMENTAL
Intervention: Selumetinib granules (25 mg) under fed conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Selumetinib capsules (50 mg [2 × 25 mg]) under fed conditions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Selumetinib granules (25 mg) under fasted conditions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Selumetinib capsules (50 mg [2 × 25 mg]) under fasted conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Selumetinib administration with a low-fat meal
Number of subjects: 24
Study: 34479574

Group type: EXPERIMENTAL
Intervention: Therapist assistance
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Orthosis assistance
Number of subjects: 8
Study: 32853900

Group type: EXPERIMENTAL
Intervention: Mindfulness training for childbirth and parenting (eight 2-hour group sessions once a week and one 3-hour session of silent meditation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care alone (Control)
Number of subjects: 0
Study: 35220356

Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated Electroconvulsive Therapy (S-ECT)
Number of subjects: 0
Study: 32051080

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine adjuvant therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 100